Michele Tanz
Family · Cape Girardeau, MONPI 1013222983
Payments from drug & device makers
Across 600 payments — averaging $21.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Enterra Medical, Inc.$825
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$680
- Aimmune Therapeutics, Inc.$568
- plus $5K from 27 others
What the payments were for
- Travel & lodging$5864%
- Food & beverage$12,35994%
- Education$2112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 160 | $3,434 |
| Johnson & Johnson(2 entities) | 84 | $1,635 |
| Takeda Pharmaceuticals U.S.A., Inc. | 63 | $1,036 |
| Enterra Medical, Inc. | 2 | $825 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 39 | $680 |
| Aimmune Therapeutics, Inc. | 27 | $568 |
| Pfizer | 30 | $528 |
| Nestle Healthcare Nutrition Inc. | 28 | $433 |
| Sanofi | 10 | $424 |
| Bristol Myers Squibb | 24 | $386 |
| Regeneron Healthcare Solutions, Inc. | 12 | $317 |
| Madrigal Pharmaceuticals | 8 | $317 |
| Intercept Pharmaceuticals, Inc. | 11 | $295 |
| Ardelyx, Inc. | 13 | $290 |
| Phathom Pharmaceuticals, Inc. | 11 | $281 |
| Amgen | 18 | $268 |
| Merck | 14 | $228 |
| Braintree Laboratories, Inc. | 13 | $205 |
| Ipsen Biopharmaceuticals, Inc | 5 | $180 |
| Vertex | 1 | $125 |
| Novo Nordisk | 1 | $111 |
| Ironwood Pharmaceuticals, Inc | 7 | $101 |
| Gilead | 1 | $89 |
| E.r. Squibb & Sons, L.L.C. | 1 | $88 |
| Lumendi LLC | 1 | $68 |
| Ferring Pharmaceuticals Inc. | 5 | $67 |
| Fresenius Kabi USA, LLC | 2 | $33 |
| Boehringer Ingelheim | 2 | $32 |
| Celltrion USA Inc. | 2 | $31 |
| Redhill Biopharma Inc. | 2 | $23 |
| QOL Medical, LLC | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Mylan Institutional Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,156 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 39 | $154,645 |
| XifaxanRifaximin | 15 | $49,867 |
| LinzessLinaclotide | 37 | $24,539 |
| MotegrityPrucalopride Succinate | 13 | $9,251 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 38 | $5,589 |
| Colestipol Hcl | 47 | $4,821 |
| MovantikNaloxegol Oxalate | 13 | $4,658 |
| Budesonide DrBudesonide | 35 | $4,442 |
| Pantoprazole Sodium | 309 | $3,390 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 15 | $2,596 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 16 | $1,944 |
| Dexlansoprazole DrDexlansoprazole | 11 | $1,523 |
| Budesonide EcBudesonide | 12 | $1,210 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 12 | $758 |
| Esomeprazole Magnesium | 17 | $669 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $3,434 | $179,18476 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $680 | $55,45653 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $1,036 | $9,25113 claims |
| Redhill Biopharma Inc.Movantik | $23 | $4,65813 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $67 | $2,59615 claims |
| Braintree Laboratories, Inc.Suflave | $205 | $1,94416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.
Other family in Cape Girardeau
- Heather MillerCape Girardeau$16K
- Christina CossouCape Girardeau$13K
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.